Increased Prevalence of Renal Diseases, Metabolic Syndrome and Fragmented Germ Cells with Reduced Endogenous Estrogen and Androgen: A Brief Study

2021 ◽  
pp. 110-120
Author(s):  
Elizabeth JeyaVardhini Samuel
Keyword(s):  
Metabolic Syndrome ◽  
Germ Cells ◽  
Renal Diseases ◽  
Endogenous Estrogen

scholarly journals The effect of hepcidin on components of metabolic syndrome in chronic kidney disease: a cross-sectional study

2020 ◽  
Vol 66 (8) ◽  
pp. 1100-1107
Author(s):  
Sibel Gökçay Bek ◽  
Berna Üstüner ◽  
Necmi Eren ◽  
Zeynep Sentürk ◽  
Betül Kalender Gönüllü
Keyword(s):  
Metabolic Syndrome ◽  
Chronic Kidney Disease ◽  
Uric Acid ◽  
Kidney Disease ◽  
Cross Sectional Study ◽  
Renal Diseases ◽  
Sectional Study ◽  
C Reactive Protein ◽  
Cross Sectional ◽  
Reactive Protein

SUMMARY BACKGROUND Hepcidin is an important regulator of iron homeostasis. OBJECTIVES This cross-sectional study was conducted to evaluate the association between hepcidin and components of metabolic syndrome in patients with chronic kidney disease (CKD). DESIGN AND SETTING 103 CKD patients and 59 healthy volunteers were included in the study from the University Hospital. METHODS Serum hepcidin levels were measured by enyzme-linked immunosorbent assay (ELISA) test. As for the study parameters, age, sex, body mass index, renal diseases, serum biochemistry, complete blood count, iron and total iron-binding capacity, ferritin, high-sensitive C-reactive protein (hsCRP), C- reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were evaluated. RESULTS The mean age of the patients was 58.63 ± 11.8 years. Hepcidin level was significantly associated with hypertension and higher uric acid levels (P < 0.05). There was a positive correlation between hepcidin and urea, uric acid, creatinine, ferritin, CRP, ESR, phosphorus, triglyceride, low-density lipoprotein (LDL), proteinuria and albuminuria in 24-hour urine collection. A negative correlation was found between hepcidin and estimated glomerular filtration rate (eGFR), hemoglobin, hematocrit, calcium, 25 OH vitamin D, pH, and bicarbonate levels. CONCLUSION Hepcidin, a well-known hormone regulator of iron metabolism, may play an important role in the pathogenesis of metabolic syndrome in patients with CKD, and further studies might delineate in-depth its potential as a promising early marker in these patients.

scholarly journals Positive association of SCD1 genetic variation and metabolic syndrome in dialysis patients in China

2020 ◽  
Vol 17 (2) ◽  
pp. 111-119
Author(s):  
Yanyan Guo ◽  
Zibo Xiong ◽  
Meiling Su ◽  
Limin Huang ◽  
Jinlan Liao ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Genetic Variation ◽  
Positive Association ◽  
Cross Sectional Study ◽  
Renal Diseases ◽  
Sectional Study ◽  
Dialysis Patients ◽  
Cross Sectional ◽  
Relationship Of ◽  
The Relationship

Aim: Metabolic syndrome (MetS) diagnosed in the dialysis patients is increasingly reported which worsens the prognosis of the renal diseases. The relationship of SCD1 with MetS is largely unknown. The purpose of this study was to investigate the relationship between SCD1 polymorphism and MetS in dialysis patients. Methods: A cross-sectional study was conducted on 323 Chinese dialysis patients, and the correlation between the seven SNPs of SCD1 gene (rs10883465, rs2060792, rs1502593, rs522951, rs3071, rs3978768 and rs1393492) and MetS was analyzed. Results: One tag-SNP (rs1393492) has significantly associated with the prevalence of MetS. Dialysis patients with rs1393492 AA genotype of SCD1 are more prone to MetS (p = 0.021). Conclusion: This study shows that the rs1393492 variations of SCD1 gene are related with the development of MetS in Chinese dialysis patients.

scholarly journals Changes in metabolic syndrome affect the health-related quality of life of community-dwelling adults

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yi-Hsuan Lin ◽  
Hsiao-Ting Chang ◽  
Yen-Han Tseng ◽  
Harn-Shen Chen ◽  
Shu-Chiung Chiang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Metabolic Syndrome ◽  
Community Dwelling ◽  
Renal Diseases ◽  
Baseline Body Mass Index ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
The Impact

AbstractMetabolic syndrome (MetS) is associated with cardiovascular diseases, type 2 diabetes, chronic renal diseases, and all-cause mortality. Furthermore, MetS is associated with poor health-related quality of life (HRQOL). However, the impact of dynamic changes in MetS on changes in the HRQOL was not previously explored. This was an eight-year, prospective cohort study in which 906 middle-aged adults from Shipai, Taipei in northern Taiwan were enrolled during 2009–2010 (baseline). Of those sampled, 427 participants completed the follow-up investigation after 8 years. The HRQOL was measured using the Short Form Health Survey (SF-36). Other variables including age, sex, marital status, level of education, smoking, alcohol consumption, baseline body mass index, and changes in physical activity were adjusted. Compared with adults who never experienced MetS, adults with persistent MetS had a negative change in mental HRQOL (β − 4.20, 95% CI − 7.54 to − 0.86, p = 0.01). The negative changes of persistent MetS on the HRQOL were in the domains of vitality and mental health (β − 4.42, 95% CI − 8.10 to − 0.73 and β − 3.47, 95% CI − 6.90 to − 0.04, respectively). Women and overweight adults were vulnerable to the detrimental effects of persistent MetS. For better HRQOL, more resources should be devoted to reversing MetS in public health.

scholarly journals Increasing Incidence of Diabetes Mellitus, Systemic Hypertension and Germ Cells with Endogenous Estrogen

2014 ◽  
Vol 04 (06) ◽  
pp. 481-488 ◽  
Author(s):  
Elizabeth Jeya Vardhini Samuel ◽  
Nagarajan Natarajan ◽  
Sanjoy George ◽  
Kiran Gkulirankal ◽  
George Eapen
Keyword(s):  
Diabetes Mellitus ◽  
Germ Cells ◽  
Systemic Hypertension ◽  
Endogenous Estrogen

scholarly journals Role of serum Cystatin C as a marker of early nephropathy in metabolic syndrome: a case control study

2018 ◽  
Vol 6 (8) ◽  
pp. 2648
Author(s):  
Hemant Goel ◽  
Onam Aggarwal ◽  
Anuj Kumar ◽  
Pramod Lali ◽  
Lal Chandra
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Cystatin C ◽  
Secondary Outcome ◽  
High Density Lipoproteins ◽  
Renal Diseases ◽  
Model Assessment ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
The Metabolic Syndrome

Background: The metabolic syndrome (MS) has become a significant public health problem and patients with MS are at higher risk for developing renal diseases. Serum Cystatin C suggested as a sensitive endogenous marker than creatinine for slight changes in GFR could be useful marker in MS.Methods: A total of 200 subjects were included. New International Diabetes Federation (IDF) definition of MS was used as inclusion criteria. Patients excluded were those with hypo/hyperthyroidism, on glucocorticoids, statins and fibrate, malignancy, cirrhosis, active liver disease and conditions affecting abdominal girth. Serum Cystatin C, insulin, creatinine, triglycerides, high density lipoproteins-cholesterol (HDL-C), fasting glucose, Urinary microalbumin and Urinary creatinine were estimated by standard method.eGFR and HOMA-IR (homeostasis model assessment of insulin resistance) were calculated. The primary outcome assessed was the occurrence of early nephropathy in MS and the secondary outcome included evaluation of early nephropathy by serum Cystatin C and eGFR. Appropriate statistical test was applied by using SPSS Version 21 software.Results: Fasting insulin levels and insulin resistance were significantly raised in MS cases. eGFR (MDRD) was lower in the MS cases (72.59±8.79mL/min/1.73m2) vs non-MS (130.34±40.75 mL/min/1.73m). Urinary microalbumin levels and serum cystatin C were significantly increased in MS and the cystatin c levels showed significant positive correlation with urinary microalbumin and negative correlation with eGFR.eGFR was found to be lower in the microalbuminuric than normoalbuminuric groups.Conclusions: Serum Cystatin C levels are higher in MS and can be useful, practical, non-invasive biomarker for evaluation of early renal involvement in MS. 

scholarly journals Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease

2021 ◽  
Vol 22 (17) ◽  
pp. 9221
Author(s):  
Hidekatsu Yanai ◽  
Hiroki Adachi ◽  
Mariko Hakoshima ◽  
Hisayuki Katsuyama
Keyword(s):  
Metabolic Syndrome ◽  
Chronic Kidney Disease ◽  
Cardiovascular Diseases ◽  
Kidney Disease ◽  
Glucose Transporter ◽  
Dominant Role ◽  
Gouty Arthritis ◽  
Renin Angiotensin System ◽  
Renal Diseases ◽  
The Metabolic Syndrome

Uric acid (UA) is synthesized mainly in the liver, intestines, and vascular endothelium as the end product of an exogenous purine from food and endogenously from damaged, dying, and dead cells. The kidney plays a dominant role in UA excretion, and the kidney excretes approximately 70% of daily produced UA; the remaining 30% of UA is excreted from the intestine. When UA production exceeds UA excretion, hyperuricemia occurs. Hyperuricemia is significantly associated with the development and severity of the metabolic syndrome. The increased urate transporter 1 (URAT1) and glucose transporter 9 (GLUT9) expression, and glycolytic disturbances due to insulin resistance may be associated with the development of hyperuricemia in metabolic syndrome. Hyperuricemia was previously thought to be simply the cause of gout and gouty arthritis. Further, the hyperuricemia observed in patients with renal diseases was considered to be caused by UA underexcretion due to renal failure, and was not considered as an aggressive treatment target. The evidences obtained by basic science suggests a pathogenic role of hyperuricemia in the development of chronic kidney disease (CKD) and cardiovascular diseases (CVD), by inducing inflammation, endothelial dysfunction, proliferation of vascular smooth muscle cells, and activation of the renin-angiotensin system. Further, clinical evidences suggest that hyperuricemia is associated with the development of CVD and CKD. Further, accumulated data suggested that the UA-lowering treatments slower the progression of such diseases.

Sign in / Sign up

Export Citation Format

Share Document